Edgemont Capital Partners Completes Sale of SCYNEXIS Contract Research and Development Business to Avista Pharma Solutions, an Ampersand Capital Partners Portfolio Company

Business News
Print
NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Today Edgemont Capital Partners, a leading independent investment banking firm providing merger and acquisition advisory services to healthcare companies, announced that it acted as exclusive financial advisor to SCYNEXIS, Inc. in the sale of its contract research and development services business to Avista Pharma Solutions. The deal was announced on July 23. SCYNEXIS, a pharmaceutical company committed to the discovery, development and

imageimage